



# Circulating biomarkers of infection and endometrial cancer risk

Kara A. Michels<sup>1,2</sup> · David Jin<sup>1</sup> · Rima Jeske<sup>3</sup> · Jolanta Lissowska<sup>4</sup> · Beata Peplowska<sup>5</sup> · Nicolas Wentzensen<sup>1</sup> · Tim Waterboer<sup>3</sup> · Britton Trabert<sup>1,6</sup>

Received: 30 April 2025 / Accepted: 26 September 2025 / Published online: 15 October 2025

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025

## Abstract

**Purpose** Incidence and mortality rates for endometrial cancer are rising. We need to better understand the etiology of this disease and identify new risk factors. We examined whether common genital infections are associated with endometrial cancer.

**Methods** Using serum samples from The Polish Endometrial Cancer Study (443 cases, 443 controls), we measured antibodies against microbial antigens with a multiplex fluorescent bead-based assay. We estimated adjusted odds ratios (OR) and 95% confidence intervals (CI), comparing women with positive versus negative serology.

**Results** Most antibodies were not associated with endometrial cancer overall, but seropositivity for *Herpes simplex virus* 2 was associated with low-grade tumors (OR 1.43 CI 1.02, 2.00). While increased risks for type II, but not type I tumors, were consistently indicated for multiple *Chlamydia trachomatis* antigens, most estimates did not reach statistical significance (e.g., Pgp3 seropositivity and type I cancers: OR 0.97 CI 0.73, 1.31; and type II: OR 2.96 CI 0.85, 10.31; heterogeneity  $p$ -value = 0.03). The strongest associations for type II tumors were observed with seropositivity for *Chlamydial* stress response proteins.

**Conclusion** Reproductive tract infections may increase risk for endometrial cancer, but the biologic mechanisms are likely both microbe- and histology-specific. Some *C. trachomatis* infections may be a risk factor for type II endometrial cancers. Given that so few risk factors for type II endometrial cancers are identified, infection-related mechanisms of carcinogenesis in the endometrium merit continued investigation.

**Keywords** Endometrial neoplasms · *Chlamydia trachomatis* · Herpesvirus 2, Human · Molecular epidemiology · Histology

## Introduction

In many countries, incidence and mortality rates for endometrial cancer have risen dramatically in the last twenty years [1]. The majority of endometrial cancers are often referred to as type I tumors; they have an endometrioid or adenocarcinoma histologic subtype (histotype) [2]. These tumors are often identified at early stages because many women will present to their physicians with postmenopausal vaginal bleeding, though only a small proportion of women with bleeding will have endometrial cancer [3]. Women who develop non-endometrioid endometrial cancers are often categorized together in research analyses because these tumors are comparatively, less common than the endometrioid subtype. Type II endometrial cancers include serous or clear cell histotypes. Women diagnosed with non-endometrioid tumors have a worse prognosis than women diagnosed with endometrioid tumors [4]. Within the United States, the incidence rates for non-endometrioid cancers have increased by

✉ Kara A. Michels  
kara.michels@einsteinmed.edu

<sup>1</sup> Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA

<sup>2</sup> Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA

<sup>3</sup> Division of Infections and Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany

<sup>4</sup> Department of Cancer Epidemiology and Prevention, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

<sup>5</sup> Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Łódź, Poland

<sup>6</sup> Department of Obstetrics and Gynecology, University of Utah, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA

approximately 3% every year between 2000 and 2015 (versus 0.5% for endometrioid tumors) [4].

The associations between endometrial cancer and factors such as parity, oral contraceptive use, smoking, and diabetes, are similar by tumor histotype [5]. Obesity is a stronger risk factor for low-grade endometrioid tumors compared to high grade endometrioid or type II tumors [5, 6]. This suggests that rising obesity rates do not fully account for the increasing incidence in non-endometrioid tumors, relative to endometrioid tumors. We need to improve our etiologic understanding of endometrial cancers and identify modifiable risk factors associated with this disease.

Research indicates that infections, such as those caused by *Chlamydia trachomatis*, may increase risk for ovarian cancer [7–11], but microbial exposures are not well-studied as risk factors for endometrial cancer. To this end, we wanted to understand if endometrial cancer is associated with exposure to infections that can potentially ascend the reproductive tract. Using data from the Polish Endometrial Cancer Study, we examined endometrial cancer risks associated with circulating antibodies specific for antigens from a range of microbes, including *C. trachomatis* and *Herpes simplex virus 2* (HSV-2).

## Materials and methods

### Study population

The Polish Cancer Study was a large case–control study of endometrial, ovarian, and breast cancer that enrolled women aged 20–74 years from Warsaw or Łódź, Poland [12, 13]. The women in the endometrial cancer study were enrolled between 2001 and 2003 [12]. Women with incident and pathologically confirmed endometrial cancer were identified through a hospital-based rapid identification system that covered approximately 85% of all cancer cases in Warsaw and Łódź; cancer registries were used to identify additional women with cancer for potential recruitment into the study [14]. To serve as population-based controls, women were selected from the Polish Electronic System, a database with demographic information for all residents of Poland [12]. The control group was frequency matched to cases on study site and age group, and was limited to women with intact uteri and without a history of breast or endometrial cancer [14]. In-person interviews were conducted to obtain information on demographics, anthropometric factors, body mass index, health history, and lifestyle behaviors at the time of study enrollment; blood samples were also collected from participants. Protocols for the Polish Endometrial Cancer Study were approved by local institutional review boards and the U.S. National Cancer Institute [12]. All participants provided written informed consent.

### Multiplex serology

We measured antibodies against antigens from *C. trachomatis*, including the commonly studied plasmid-encoded virulence factor Pgp3, major outer membrane proteins (MOMP), translocated actin-recruiting phosphoprotein (Tarp, divided into C- and N- terminal fragments), and heat shock protein 60 variant 1 (HSP60-1); the other antigens from *C. trachomatis* are named for their gene sequence and may encode proteins with known or unknown function. We also assessed antigens from microbes known to cause reproductive tract pathologies, including *Mycoplasma genitalium* (MgPaN and rMgPa, antigens from two regions of the adhesin P1), HSV-2 (mgG, mucin-like glycoprotein), and *Human Papilloma viruses* (HPV) 16 and 18 (major capsid proteins L1), as well as antigens from *Polyomaviruses* BK, JC, and 6 (VP1, viral capsid protein 1) as positive controls (i.e., we expected seropositivity to be high, but no association with cancer).

Serum samples were sent to the German Cancer Research Center (Heidelberg, Germany) for the assessment of antibody seropositivity to selected microbial antigens. The methods for the multiplex serology assay have been previously described [7, 15]. In brief, the assay is a bead-based suspension array in which selected antigens are expressed as recombinant glutathione S-transferase fusion proteins in *Escherichia coli*; the proteins are then loaded onto fluorescently labeled polystyrene beads (Luminex Corp., Austin, Texas, USA) derivatized with glutathione-casein. Study serum samples were incubated with the beads at a final 1:100 dilution. Biotinylated goat anti-human IgG/IgM/IgA secondary antibodies (Jackson ImmunoResearch, West Grove, Pennsylvania, USA) and Streptavidin-R-Phycoerythrin (MossBio, Pasadena, MD, USA) were used to quantify human antibodies bound to the beads. The final fluorescence corresponded to the amount of serum antibodies (i.e., “antibody levels”) and was measured in units of median fluorescence intensity (MFI) on a Luminex 200 analyzer. Final MFI values were estimated by subtracting the MFI of a serum-specific GST control and the bead-specific background fluorescence from the raw MFI values [15]. Continuous final MFI values were dichotomized as seropositive or seronegative based on previously used cut-points, which were adjusted to reflect the measured signal distribution [7, 16]. Three serum pools were included in duplicate across batches as quality control samples. The average concordance of seropositivity status between these samples was 92.6% across all antigens (median = 93.6%, standard deviation = 7.9%, minimum = 71.%, maximum = 100%).

### Statistical analyses

We used adjusted conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) for

endometrial cancer, comparing women with positive versus negative serology for antibodies against each antigen. The main models were conditioned on matching factors (age and study site) and then adjusted for history of oral contraceptive use (never/ever), and current smoking (never, past, current), body mass index (< 25, 25–29.9, 30 + kg/m<sup>2</sup>), and menopausal status (premenopausal, postmenopausal).

In secondary analyses, we evaluated associations by endometrial tumor type (I and II) and grade (low: well or moderately differentiated, high: poorly differentiated). In these analyses, we used unconditional multinomial logistic regression adjusted for the aforementioned matching factors and variables, with controls as the reference group. For the tumor type analyses, we also ran cases-only models comparing women with type II tumors to type I tumors (as the reference group) to estimate p values for heterogeneity (p-het) from Wald tests for each antigen of interest. Data missingness was minimal and a complete-case modeling approach was used. An  $\alpha$  of 0.05 was used to estimate statistical significance, all statistical tests were two-sided, and analyses were performed using SAS (SAS Institute, Cary, NC).

## Results

Basic characteristics of the participants in the Polish Endometrial Cancer study are described in Table 1. When considering all endometrial cancer types together, our data suggest that most antibodies were not associated with endometrial cancer (Table 2; Supplemental Table S1). An increased risk of borderline statistical significance for any endometrial cancer was indicated with seropositivity against the *C. trachomatis* antigen, CT\_418 (odds ratio [OR] 1.79 and 95% confidence interval [CI] 0.96, 3.23). A modest association was suggested for seropositivity against the *HSV-2* antigen, mgG (OR 1.21 CI 0.87, 1.69). Positive serology for *Polyomavirus JC* was associated with a reduced risk for endometrial cancer, but most women in this population (75–97%) were expectedly seropositive for the virus.

Four hundred thirty one women were diagnosed with type I endometrial cancers, while 12 women were diagnosed with type II tumors (Table 3 and Supplementary Table S1). The effect magnitudes for *HSV-2* seropositivity were comparable between type I (OR 1.26 CI 0.93, 1.71) and type II tumors (OR 1.40 CI 0.42, 4.06; p for heterogeneity 0.760). *HSV-2* seropositivity was associated with risk for low-grade tumors (OR 1.43 CI 1.02, 2.00;  $n = 291$ ; not tabulated).

While modest risks for type I cancers were suggested with seropositivity against the *C. trachomatis* antigens CT\_418 and CT\_664C, null associations could not be ruled out (Table 3). Interestingly, the magnitude of the associations for multiple

**Table 1** Selected characteristics of cases and controls from the Polish Endometrial Cancer Study

|                                      | Cases<br>$n = 443$ |      | Controls<br>$n = 443$ |      |
|--------------------------------------|--------------------|------|-----------------------|------|
|                                      | $n^a$              | %    | $n$                   | %    |
| Age category in 5-yr intervals       |                    |      |                       |      |
| < 35                                 | 3                  | 0.7  | 3                     | 0.7  |
| 35–39                                | 2                  | 0.5  | 2                     | 0.5  |
| 40–44                                | 9                  | 2.0  | 9                     | 2.0  |
| 45–49                                | 33                 | 7.5  | 33                    | 7.5  |
| 50–54                                | 55                 | 12.4 | 55                    | 12.4 |
| 55–59                                | 82                 | 18.5 | 82                    | 18.5 |
| 60–64                                | 86                 | 19.4 | 86                    | 19.4 |
| 65–69                                | 95                 | 21.4 | 95                    | 21.4 |
| 70+                                  | 78                 | 17.6 | 78                    | 17.6 |
| Body Mass Index (kg/m <sup>2</sup> ) |                    |      |                       |      |
| < 25                                 | 118                | 26.6 | 155                   | 35.0 |
| 25–29.9                              | 167                | 37.7 | 173                   | 39.1 |
| 30+                                  | 153                | 34.5 | 108                   | 24.4 |
| Menopausal Status                    |                    |      |                       |      |
| Premenopausal                        | 6                  | 1.4  | 69                    | 15.6 |
| Postmenopausal                       | 437                | 98.7 | 373                   | 84.2 |
| Highest education level attained     |                    |      |                       |      |
| Did not complete high school         | 157                | 35.7 | 178                   | 40.3 |
| High school graduate                 | 160                | 36.4 | 155                   | 35.1 |
| Some college, professional training  | 32                 | 7.3  | 40                    | 9.1  |
| College graduate                     | 91                 | 20.7 | 69                    | 15.6 |
| Smoking status                       |                    |      |                       |      |
| Never                                | 284                | 64.1 | 224                   | 50.6 |
| Past                                 | 79                 | 17.8 | 90                    | 20.3 |
| Current                              | 80                 | 18.1 | 129                   | 29.1 |
| Oral contraceptive use               |                    |      |                       |      |
| Never                                | 420                | 95.2 | 415                   | 94.5 |
| Ever                                 | 21                 | 4.8  | 24                    | 5.5  |

<sup>a</sup>Columns and percentages may not sum to total due to missing data; less than 2% of the population were missing data on any of these variables

*C. trachomatis* antigens, including Pgp3, qualitatively differed by tumor type (Pgp3 seropositivity, type I: OR 0.97 CI 0.73, 1.31; and type II: OR 2.96 CI 0.85, 10.31; p-het 0.031). Across the *C. trachomatis* antigens evaluated, we consistently observed potential 2- to eightfold increases in the ORs for type II endometrial cancers, while ORs for type I cancers were near-null in magnitude—though the confidence intervals for only one of the type II associations reached statistical significance (p-het < 0.10). The strongest association we identified for type II tumors was with CT\_418 seropositivity (OR 7.90 CI 1.83, 34.05; p-het 0.024).

**Table 2** Associations between seropositivity against selected microbial antigens and endometrial cancer

| Microbe and Antigen           | Seropositivity          |      |            |      | Association with endometrial cancer |            |
|-------------------------------|-------------------------|------|------------|------|-------------------------------------|------------|
|                               | Cases                   |      | Controls   |      | OR <sup>b</sup>                     | 95% CI     |
|                               | <i>n</i> + <sup>a</sup> | % +  | <i>n</i> + | % +  |                                     |            |
| <i>Chlamydia trachomatis</i>  |                         |      |            |      |                                     |            |
| Pgp3                          | 184                     | 41.5 | 181        | 40.9 | 1.11                                | 0.82, 1.50 |
| MOMP-A                        | 158                     | 35.7 | 159        | 35.9 | 0.96                                | 0.70, 1.32 |
| MOMP-D                        | 175                     | 39.5 | 183        | 41.3 | 0.98                                | 0.72, 1.35 |
| MOMP-L2                       | 156                     | 35.2 | 164        | 37.0 | 1.10                                | 0.79, 1.54 |
| Tarp-F1                       | 203                     | 45.8 | 212        | 47.9 | 0.88                                | 0.65, 1.19 |
| Tarp-F2                       | 230                     | 51.9 | 213        | 48.1 | 1.16                                | 0.85, 1.59 |
| HSP60-1                       | 236                     | 53.3 | 228        | 51.5 | 1.13                                | 0.82, 1.56 |
| CT_067 (TroA)                 | 152                     | 34.3 | 149        | 33.6 | 1.04                                | 0.74, 1.46 |
| CT_223                        | 207                     | 46.7 | 202        | 45.6 | 1.00                                | 0.73, 1.35 |
| CT_418                        | 39                      | 8.8  | 25         | 5.6  | 1.76                                | 0.96, 3.23 |
| CT_664C                       | 197                     | 44.5 | 188        | 42.4 | 1.20                                | 0.88, 1.65 |
| CT_664N                       | 137                     | 30.9 | 133        | 30.0 | 1.08                                | 0.77, 1.52 |
| CT_798                        | 191                     | 43.1 | 184        | 41.5 | 1.08                                | 0.80, 1.46 |
| <i>Mycoplasma genitalium</i>  |                         |      |            |      |                                     |            |
| MgPaN                         | 204                     | 46.1 | 216        | 48.8 | 0.91                                | 0.66, 1.26 |
| rMgPa                         | 250                     | 56.4 | 257        | 58.0 | 1.02                                | 0.74, 1.40 |
| <i>Herpes simplex virus 2</i> |                         |      |            |      |                                     |            |
| mgG                           | 160                     | 36.1 | 137        | 30.9 | 1.21                                | 0.87, 1.69 |
| <i>Human Papilloma virus</i>  |                         |      |            |      |                                     |            |
| 16L1                          | 22                      | 5.0  | 23         | 5.2  | 0.81                                | 0.41, 1.60 |
| 18L1                          | 43                      | 9.7  | 44         | 9.9  | 0.99                                | 0.60, 1.63 |
| <i>Polyomavirus</i>           |                         |      |            |      |                                     |            |
| BKVP1                         | 433                     | 97.7 | 432        | 97.5 | 1.29                                | 0.42, 3.97 |
| JCVP1                         | 333                     | 75.2 | 361        | 81.5 | 0.62                                | 0.42, 0.92 |
| HPyV6VP1                      | 412                     | 93.0 | 398        | 89.8 | 1.62                                | 0.86, 3.06 |

<sup>a</sup>Seropositive (+)<sup>b</sup>Logistic regression models conditioned on matching factors (age and study site) and adjusted for oral contraceptive use, smoking, body mass index, and menopausal status

## Discussion

To our knowledge, this is the first study to report on associations between endometrial cancer and exposure to *Chlamydia trachomatis*. Increased risks for type II tumors were suggested with antibody seropositivity to several *C. trachomatis* antigens; an eightfold increased risk associated with the CT\_418 antigen reached statistical significance. In our study, most women diagnosed with type II cancers had serous tumors, but due to small sample sizes, we were unable to evaluate associations with the serous histotype alone—therefore, these results require replication and expansion. Although some of our estimates were not statistically significant, the consistency in the direction of the observed associations across chlamydial antigens supports the idea that chlamydia infection may be a promising avenue of etiologic research for endometrial cancer.

Seropositivity to *C. trachomatis* has been associated with increased risk for ovarian cancer in multiple studies, but the risks vary by population, tumor histotype, and the antigen of interest [7–11]. Most of these studies only evaluate seropositivity against a few antigens like Pgp3 and HSP60-1. We previously used data from the Polish Ovarian Cancer Study and a nested case–control study in The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) to evaluate ovarian cancer risk associated with seropositivity to multiple *C. trachomatis* antigens, though we did not assess all of the antigens of interest from the present analysis (e.g., CT\_418) [7]. In the data from Poland, the highest circulating levels of antibodies against Pgp3, MOMP-A, and MOMP-L2, were associated with ovarian cancer (ORs between 1.45 and 1.63) [7]. Similar effect magnitudes were observed within PLCO when higher Poland Study-based thresholds were used to determine seropositivity [7]. Interestingly, risks associated

**Table 3** Seropositivity against selected *Chlamydia trachomatis* and *Herpes simplex virus 2* antigens and endometrial cancer risk, by classical tumor type

| Microbe and Antigen           | Tumor Type                            |      |                     |                         |             |                    | P-het        |
|-------------------------------|---------------------------------------|------|---------------------|-------------------------|-------------|--------------------|--------------|
|                               | Type 1 <sup>a</sup><br><i>n</i> = 431 |      |                     | Type 2<br><i>n</i> = 12 |             |                    |              |
|                               | Cases<br><i>n</i> + <sup>b</sup>      | OR   | 95% CI <sup>c</sup> | Cases<br><i>n</i> +     | OR          | 95% CI             |              |
| <i>Chlamydia trachomatis</i>  |                                       |      |                     |                         |             |                    |              |
| Pgp3 <sup>d</sup>             | 176                                   | 0.97 | 0.73, 1.31          | 8                       | 2.96        | 0.85, 10.31        | <b>0.031</b> |
| MOMP-A                        | 153                                   | 0.96 | 0.71, 1.30          | 5                       | 1.30        | 0.39, 4.36         | 0.635        |
| MOMP-D                        | 169                                   | 0.89 | 0.66, 1.19          | 6                       | 1.45        | 0.45, 4.70         | 0.368        |
| MOMP-L2                       | 149                                   | 0.91 | 0.67, 1.23          | 7                       | 2.69        | 0.81, 8.93         | <b>0.050</b> |
| Tarp-F1                       | 195                                   | 0.79 | 0.59, 1.06          | 8                       | 1.94        | 0.56, 6.67         | 0.110        |
| Tarp-F2                       | 221                                   | 1.06 | 0.79, 1.42          | 9                       | 3.39        | 0.88, 13.01        | <b>0.073</b> |
| HSP60-1                       | 230                                   | 1.09 | 0.81, 1.45          | 6                       | 1.10        | 0.33, 3.66         | 0.906        |
| CT_067 (TroA)                 | 145                                   | 0.96 | 0.71, 1.30          | 7                       | 2.78        | 0.84, 9.25         | <b>0.052</b> |
| CT_223                        | 198                                   | 0.93 | 0.70, 1.24          | 9                       | 3.29        | 0.86, 12.56        | <b>0.034</b> |
| CT_418                        | 36                                    | 1.50 | 0.84, 2.68          | 3                       | <b>7.90</b> | <b>1.83, 34.05</b> | <b>0.024</b> |
| CT_664C                       | 192                                   | 1.26 | 0.93, 1.69          | 5                       | 1.25        | 0.38, 4.17         | 0.994        |
| CT_664N                       | 131                                   | 1.04 | 0.76, 1.42          | 6                       | 3.13        | 0.92, 10.63        | <b>0.060</b> |
| CT_798                        | 183                                   | 0.94 | 0.70, 1.25          | 8                       | 2.47        | 0.71, 8.56         | <b>0.097</b> |
| <i>Herpes simplex virus 2</i> |                                       |      |                     |                         |             |                    |              |
| mgG                           | 155                                   | 1.26 | 0.93, 1.71          | 5                       | 1.40        | 0.42, 4.06         | 0.760        |

<sup>a</sup>Type I tumors include those with an endometrioid, mucinous, malignant mixed Mullerian, or Mixed histologic subtype. Type II tumors include those with clear cell and papillary serous histologic subtypes

<sup>b</sup> Number of women with cancer who were seropositive (+)

<sup>c</sup> Adjusted for age, study site, oral contraceptive use, smoking, body mass index, and menopausal status

<sup>d</sup>Statistically significant results are in bold. P-het in bold suggest potential type-specific associations, as defined by p for heterogeneity < 0.10

with Pgp3 were similar across ovarian cancer histotypes in the Poland data (serous: OR 2.24 CI 1.12, 4.46 versus non-serous: OR 2.06 CI 1.04, 4.08) [7].

We have not identified other studies reporting on *HSV-2* and endometrial cancer risk, though in a 1992 case series, researchers detected circulating *Herpesvirus* antibodies (type not specified) in 13 out of 20 women with endometrial cancer (most of whom had adenocarcinomas) [17]. *HSV-2* exposure does not appear to be a strong risk factor for ovarian cancer, but any associations may depend on other infections or tumor histotype. For example, results from the Nurse's Health Studies I and II indicated that *C. trachomatis* infection was associated ovarian cancer (risk ratio [RR] 2.07 CI 1.25–3.43), while *HSV-2* infection was not (RR 1.38 CI 0.79, 2.42) [11]. However, when examining seropositivity to these pathogens together, ovarian cancer risks were strongest among women exposed to both *C. trachomatis* and *HSV-2* (reference group: unexposed women; only Pgp3 seropositive: RR 1.67 CI 0.97, 2.87; only *HSV-2* seropositive: RR 0.73 CI 0.33, 1.62; both Pgp3 and *HSV-2* seropositive: RR 3.26 CI 1.25, 8.51) [11]. A study from the European Prospective Investigation into Cancer and Nutrition cohort reported an association between *HSV-2* infection

and endometrioid, but not serous, ovarian cancers (RR for endometrioid ovarian cancer: 2.35 CI 1.24, 4.43) [9].

It is important to remember that the Poland Endometrial Cancer Study was conducted over twenty years ago, before the recently observed increases in the incidence of endometrial cancer, especially in the United States [4]. We are not able to make direct connections between chlamydia infections and these trends with our data. This being said, the biologic plausibility for *C. trachomatis* increasing cancer risk merits discussion. The bacterium is known to modulate multiple cancer-associated metabolic pathways in host cells, including those involving tumor protein p53 and phosphatidylinositol 3-kinases (i.e., PI3K) [18]. Aberrant p53 staining and mutations in the p53 gene are a hallmark of serous endometrial cancers [2]. Pelvic inflammatory disease (PID) is also hypothesized to serve as a potential mechanistic link between reproductive tract infections and gynecologic cancers. Most PID is presumed to be caused by *C. trachomatis* or *Neisseria gonorrhea*, but contributions from other pathogens are increasingly being recognized [19, 20]. As such, this “inflammatory state” actually represents a range of heterogeneous exposures. Two research groups have explored associations between medical record documentation of PID

and endometrial cancer, with both concluding that PID is not associated—but interpreting these results is difficult, given that the modeling strategy in one study only accounted for age and calendar period, while models in the other study were arguably overadjusted for comorbid conditions [21, 22].

The unique antigens that we evaluated also inform potential mechanistic links between chlamydia infection and cancer. For example, (TroA/YtgA) is a protein that may enable *C. trachomatis* survival in the face of environmental iron depletion; it is known to be expressed across multiple serovars [23, 24]. Our strongest association for type II endometrial cancers was observed with CT<sub>418</sub>, though it should be noted that while 9% of all women with endometrial cancer in our study were seropositive for this antigen, only three women with type II tumors were seropositive. We are not aware of any other studies that have evaluated the seroprevalence of this antigen. This protein is a member of the OGB superfamily of GTPases encoded by the gene *yhbZ* [25]. Increased transcription of the *obg* gene, though not necessarily translation, may be integral to stress responses across chlamydial species, especially when confronted with tryptophan depletion mediated by host interferon gamma secretion [26, 27]. In response to interferon gamma, intracellular *C. trachomatis* enters into a non-infectious, but persistent and metabolically active form (called a reticulate body); this state is also correlated with decreased levels of MOMP [28]. Taken together, the research on these antigens suggests that specific metabolic mechanisms enabling *C. trachomatis* persistence should be investigated in the context of gynecologic carcinogenesis—and for endometrial cancer, our analysis has demonstrated the importance of examining these potential connections across tumor histotypes.

We must acknowledge, while most of the antigens we evaluated are expected to be *C. trachomatis* derived, HSP60 for example, is a highly conserved protein across *Chlamydia* species [29]. Similarly, most of our antigens are likely produced across the serovars of *C. trachomatis*, which are defined by their unique major outer membrane proteins (MOMPs). Serovars A through C are associated with ocular chlamydial infections, serovars D through K cause genital infections, and serovars L1 through L3 cause lymphogranuloma venereum, but there can be overlap [30, 31]. Many of the chlamydial antigens selected for our multiplex assay were identified from a whole proteome array of serovar D [32], and for MOMP, we additionally evaluated seropositivity to the serovar-specific homologs of these proteins. The strongest MOMP association that we identified was between MOMP-L2 and type II endometrial cancers. Seropositivity to Pgp3, one of the most commonly used metrics for assessing prior *C. trachomatis* exposure, is also used in studies of ocular infection (trachoma) [33]. The Pgp3 protein is expressed across *C. trachomatis* strains, though the level

of transcription will vary based on a strain's propensity for infecting specific tissue types [34]. It is possible that variation in the prevalence of *C. trachomatis* infections by serovar contributes to disparate findings across study populations with regard to ovarian cancer risk associated with Pgp3.

A strength of our study is the use of circulating antibodies to measure infection history. Circulating antibodies are a reliable and informative way to assess infectious exposures in research settings. Antibodies are markers for specific microbes, and seropositivity is a metric that does not depend upon recall of infections (which can be asymptomatic) or upon subjective definitions of behaviors that might be used as proxies for infectious exposures (e.g., querying sexual history to assess sexually transmitted infection exposures). However, circulating antibodies are less useful for determining when an infection occurred, as women may have higher antibodies levels due to more recent infections or more severe infections (or perhaps, persistent infections). The extent to which circulating antibody concentrations wane over time is difficult to assess and likely dependent upon many factors, but Pgp3 seropositivity has been observed to persist for ten or more years in one study of reproductive aged women (with 97% of seropositive 26 year olds still being seropositive at age 38) [35]. We previously noted that *C. trachomatis* antibody levels were higher in the Poland Ovarian Cancer Study, relative to the older participants in PLCO [7]. If future studies can establish seropositivity cut-points that differentiate between recent or persistent infections, which we were not able to do, the latency between chlamydia infection and potential oncogenesis could be better understood.

From a clinical perspective, the odds ratio magnitudes we observed can be considered modest; these associations imply that the measurement of antibody seropositivity alone would not offer utility for endometrial cancer risk screening [36]. Additionally, we did not correct our findings for multiple testing because this was a hypothesis-generating study, so larger studies with more power will help confirm these exploratory results. However, our findings should inform etiologic investigations of endometrial cancer. Given that so few risk factors for serous endometrial cancers are identified [5], our study supports the need for continued investigation of reproductive tract infections as risk factors for this disease, particularly those stemming from *C. trachomatis*.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s10552-025-02080-6>.

**Acknowledgments** Preliminary results from this research were presented at the 2022 Society for Epidemiologic Research annual meeting and the 2023 “Approaches to Curtail Endometrial Cancer Incidence and Mortality” meeting.

**Author contributions** Conceptualization: BT, NW, TW; Formal Analysis: DJ, BT; Funding acquisition: BT; Investigation: KAM, RJ, TW, BT;

Resources: JL, BP; Supervision: BT; Visualization: KAM, BT; Writing – original draft: KAM; Writing – review & editing: All authors.

**Funding** This work was supported by the intramural research program of the U.S. National Cancer Institute, National Institutes of Health.

**Data availability** Data from this study will be shared upon request. Please contact Nicolas Wentzensen for more information: [wentzenn@mail.nih.gov].

## Declarations

**Conflict of interest** None of the authors has conflicts to disclose.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Ervik M, Lam F, Laversanne M, Ferlay J, Bray F. Global Cancer Observatory: Cancer Over Time. "Estimated annual percentage change of age-standardized rates per 100 000: uterine corpus cancer, incidence, females (Multiple regions, including Poland and USA)". International Agency for Research on Cancer; 2022. Accessed August 2022. <https://gco.iarc.fr/overtime/en>
2. Murali R, Soslow RA, Weigelt B (2014) Classification of endometrial carcinoma: more than two types. *Lancet Oncol* 15(7):e268–e278
3. Clarke MA, Long BJ, Del Mar MA, Arbyn M, Bakkum-Gamez JN, Wentzensen N (2018) Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. *JAMA Intern Med* 178(9):1210–1222
4. Clarke MA, Devesa SS, Harvey SV, Wentzensen N (2019) Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. *J Clin Oncol* 37:1895–908
5. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV Jr, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL (2013) Type I and II endometrial cancers: have they different risk factors? *J Clin Oncol* 31(20):2607–2618
6. Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino R (2013) Etiologic heterogeneity in endometrial cancer: evidence from a gynecologic oncology group trial. *Gynecol Oncol* 129(2):277–284
7. Trabert B, Waterboer T, Idahl A, Brenner N, Brinton LA, Butt J, Coburn SB, Hartge P, Hufnagel K, Inturrisi F, Lissowska J, Mentzer A, Peplonska B, Sherman ME, Wills GS, Woodhall SC, Pawlita M, Wentzensen N (2019) Antibodies against chlamydia trachomatis and ovarian cancer risk in two independent populations. *J Natl Cancer Inst* 111(2):129–136
8. Ness RB, Goodman MT, Shen C, Brunham RC (2003) Serologic evidence of past infection with *Chlamydia trachomatis*, in relation to ovarian cancer. *J Infect Dis* 187(7):1147–1152
9. Idahl A, Lundin E, Jurstrand M, Kumlin U, Elgh F, Ohlson N, Ottander U (2011) *Chlamydia trachomatis* and *Mycoplasma genitalium* plasma antibodies in relation to epithelial ovarian tumors. *Infect Dis Obstet Gynecol*. <https://doi.org/10.1155/2011/824627>
10. Shanmughapriya S, SenthilKumar G, Vinodhini K, Das BC, Vasanthi N, Natarajaseenivasan K (2012) Viral and bacterial aetiologies of epithelial ovarian cancer. *Eur J Clin Microbiol Infect Dis* 31(9):2311–2317
11. Fortner RT, Terry KL, Bender N, Brenner N, Hufnagel K, Butt J, Waterboer T, Tworoger SS (2019) Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies. *Br J Cancer* 120(8):855–860
12. Brinton LA, Sakoda LC, Lissowska J, Sherman ME, Chatterjee N, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Garcia-Closas M (2007) Reproductive risk factors for endometrial cancer among Polish women. *Br J Cancer* 96(9):1450–1456
13. Garcia-Closas M, Brinton LA, Lissowska J, Richesson D, Sherman ME, Szeszenia-Dabrowska N, Peplonska B, Welch R, Yeager M, Zatonski W, Chanock SJ (2007) Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study. *BMC Cancer* 7:60
14. Yang HP, Brinton LA, Platz EA, Lissowska J, Lacey JV Jr., Sherman ME, Peplonska B, Garcia-Closas M (2010) Active and passive cigarette smoking and the risk of endometrial cancer in Poland. *Eur J Cancer* 46(4):690–696
15. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M (2005) Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. *Clin Chem* 51(10):1845–1853
16. Hufnagel K, Hoenderboom B, Harmel C, Rohland JK, van Benthem BHB, Morré SA, Waterboer T (2019) Chlamydia trachomatis whole-proteome microarray analysis of the Netherlands chlamydia cohort study. *Microorganisms* 7(12):703
17. Draca P, Damjanovic J, Draca T, Vukovic V (1992) Viruses as possible etiological factors in human genital cancer. *Eur J Gynaecol Oncol* 13(2):193–199
18. Elwell C, Mirrashidi K, Engel J (2016) Chlamydia cell biology and pathogenesis. *Nat Rev Microbiol* 14(6):385–400
19. Davies B, Turner KM, Leung S, Yu BN, Frølund M, Benfield T, Blanchard J, Westh H, Ward H (2017) Comparison of the population excess fraction of *Chlamydia trachomatis* infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: systematic review and retrospective cohort analysis. *PLoS ONE* 12(2):e0171551
20. Mitchell CM, Anyalechi GE, Cohen CR, Haggerty CL, Manhart LE, Hillier SL (2021) Etiology and diagnosis of pelvic inflammatory disease: looking beyond Gonorrhea and Chlamydia. *J Infect Dis* 224(12 Suppl 2):S29–s35
21. Sogaard KK, Leisner MZ, Laugesen K, Farkas DK, Karagas MR, Sorensen HT (2019) Pelvic inflammatory disease and risk of cancer: a nationwide cohort study. *Int J Gynaecol Obstet* 149:107
22. Shen CC, Hu LY, Yang AC, Chiang YY, Hung JH, Tsai SJ (2016) Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study. *BMC Cancer* 16(1):839

23. Miller JD, Sal MS, Schell M, Whittimore JD, Raulston JE (2009) *Chlamydia trachomatis* YtgA is an iron-binding periplasmic protein induced by iron restriction. *Microbiology (Reading)* 155(Pt 9):2884–2894
24. Hokynar K, Korhonen S, Norja P, Paavonen J, Puolakkainen M (2017) Antibody to *Chlamydia trachomatis* proteins, TroA and HtrA, as a biomarker for *Chlamydia trachomatis* infection. *Eur J Clin Microbiol Infect Dis* 36(1):49–56
25. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, Mitchell W, Olinger L, Tatusov RL, Zhao Q, Koonin EV, Davis RW (1998) Genome sequence of an obligate intracellular pathogen of humans: *Chlamydia trachomatis*. *Science*. 282(5389):754–9
26. Ouellette SP, Rueden KJ, Rucks EA (2016) Tryptophan codon-dependent transcription in *Chlamydia pneumoniae* during gamma interferon-mediated tryptophan limitation. *Infect Immun* 84(9):2703–2713
27. Polkinghorne A, Hogan RJ, Vaughan L, Summersgill JT, Timms P (2006) Differential expression of chlamydial signal transduction genes in normal and interferon gamma-induced persistent *Chlamydia pneumoniae* infections. *Microbes Infect* 8(1):61–72
28. Beatty WL, Byrne GI, Morrison RP (1993) Morphologic and antigenic characterization of interferon gamma-mediated persistent *Chlamydia trachomatis* infection in vitro. *Proc Natl Acad Sci USA* 90(9):3998–4002
29. Cappello F, Conway de Macario E, Di Felice V, Zummo G, Macario AJ (2009) Chlamydia trachomatis infection and anti-Hsp60 immunity: the two sides of the coin. *PLoS Pathog*. 5(8):e1000552
30. MacDonald AB (1985) Antigens of *Chlamydia trachomatis*. *Rev Infect Dis* 7(6):731–736
31. Wang SP, Grayston JT (1974) Human serology in *Chlamydia trachomatis* infection with microimmunofluorescence. *J Infect Dis* 130(4):388–397
32. Hufnagel K, Lueong S, Willhauck-Fleckenstein M, Hotz-Wagenblatt A, Miao B, Bauer A, Michel A, Butt J, Pawlita M, Hoheisel JD, Waterboer T (2018) Immunoprofiling of *Chlamydia trachomatis* using whole-proteome microarrays generated by on-chip in situ expression. *Sci Rep* 8(1):7503
33. Kaur H, Dize L, Munoz B, Gaydos C, West SK (2018) Evaluation of the reproducibility of a serological test for antibodies to *Chlamydia trachomatis* pgp3: a potential surveillance tool for trachoma programs. *J Microbiol Methods* 147:56–58
34. Ferreira R, Borges V, Nunes A, Borrego MJ, Gomes JP (2013) Assessment of the load and transcriptional dynamics of *Chlamydia trachomatis* plasmid according to strains' tissue tropism. *Microbiol Res* 168(6):333–339
35. Horner PJ, Wills GS, Righarts A, Vieira S, Kounali D, Samuel D, Winston A, Muir D, Dickson NP, McClure MO (2016) *Chlamydia trachomatis* Pgp3 antibody persists and correlates with self-reported infection and behavioural risks in a blinded cohort study. *PLoS ONE* 11(3):e0151497
36. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. *Am J Epidemiol* 159(9):882–890

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.